CO2019011967A2 - Compuestos antitumorales - Google Patents

Compuestos antitumorales

Info

Publication number
CO2019011967A2
CO2019011967A2 CONC2019/0011967A CO2019011967A CO2019011967A2 CO 2019011967 A2 CO2019011967 A2 CO 2019011967A2 CO 2019011967 A CO2019011967 A CO 2019011967A CO 2019011967 A2 CO2019011967 A2 CO 2019011967A2
Authority
CO
Colombia
Prior art keywords
tumor compounds
tumor
compounds
cancer
compound
Prior art date
Application number
CONC2019/0011967A
Other languages
English (en)
Spanish (es)
Inventor
Marchante Maria Del Carmen Cuevas
Solloso Andres Francesch
Barrasa Valentin Martinez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of CO2019011967A2 publication Critical patent/CO2019011967A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
CONC2019/0011967A 2017-04-27 2019-10-25 Compuestos antitumorales CO2019011967A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17382228 2017-04-27
EP17382497 2017-07-26
PCT/EP2018/060868 WO2018197663A1 (fr) 2017-04-27 2018-04-27 Composés anticancéreux

Publications (1)

Publication Number Publication Date
CO2019011967A2 true CO2019011967A2 (es) 2020-02-18

Family

ID=62063080

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0011967A CO2019011967A2 (es) 2017-04-27 2019-10-25 Compuestos antitumorales

Country Status (37)

Country Link
US (5) US10538535B2 (fr)
EP (5) EP4047002B1 (fr)
JP (5) JP7186723B2 (fr)
KR (3) KR102491180B1 (fr)
CN (4) CN110621678A (fr)
AU (4) AU2018260314C1 (fr)
BR (1) BR112019022282A2 (fr)
CA (1) CA3061518A1 (fr)
CL (1) CL2019003057A1 (fr)
CO (1) CO2019011967A2 (fr)
CY (3) CY1121884T1 (fr)
DK (5) DK3615544T3 (fr)
EC (1) ECSP19083967A (fr)
ES (5) ES2944344T3 (fr)
FI (3) FI4047002T3 (fr)
HK (2) HK1255938B (fr)
HR (5) HRP20230433T1 (fr)
HU (5) HUE046109T2 (fr)
IL (3) IL270153B2 (fr)
JO (1) JOP20190254A1 (fr)
LT (5) LT4047002T (fr)
MA (2) MA44021B1 (fr)
MD (5) MD3615544T2 (fr)
ME (2) ME03466B (fr)
MX (3) MX2019012812A (fr)
MY (1) MY198004A (fr)
PH (1) PH12019550224A1 (fr)
PL (5) PL4047002T3 (fr)
PT (2) PT3395820T (fr)
RS (5) RS59174B1 (fr)
SG (2) SG11201909841RA (fr)
SI (5) SI3615544T1 (fr)
TN (2) TN2019000211A1 (fr)
TW (3) TW202344509A (fr)
UY (1) UY37706A (fr)
WO (1) WO2018197663A1 (fr)
ZA (1) ZA201907119B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
CA3158733A1 (fr) * 2019-11-21 2021-05-27 Pilar Calvo Procedes de traitement du cancer du poumon a petites cellules avec des formulations de lurbinectedine
CA3175426A1 (fr) 2020-04-21 2021-10-28 Alfonso Latorre Lozano Conjugues medicament-anticorps
TW202144369A (zh) * 2020-04-26 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 海鞘素類衍生物及其製備方法與醫藥用途
WO2022243482A1 (fr) 2021-05-19 2022-11-24 Pharma Mar, S.A. Schémas posologiques pour l'écubectédine

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3205220A (en) 1961-10-26 1965-09-07 Lilly Co Eli Leurosidine and leurocristine and their production
US4762949A (en) 1979-06-20 1988-08-09 University Of Illinois Foundation Acyl and carbamimidoyl alkanediamines
GB2058047B (en) 1979-07-11 1983-09-21 Asahi Chemical Ind Amides and amidines
FR2461995A1 (fr) 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
US4782135A (en) 1980-09-12 1988-11-01 Board Of Trustees, University Of Illinois Composition of matter and process
US5137870A (en) 1980-09-12 1992-08-11 The Board Of Trustees Of The University Of Illinois Didemnins and nordidemnins
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4548814A (en) 1980-12-18 1985-10-22 The Board Of Trustees Of The University Of Illinois Composition of matter and process
JPS5922518A (ja) 1982-07-29 1984-02-04 余合住金産業株式会社 洋服タンス
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
HU201672B (en) 1984-12-28 1990-12-28 Conpharm Ab Process for producing pharmaceutical compositions comprising podophyllotoxin
US4644072A (en) 1985-04-12 1987-02-17 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
EP0220453B1 (fr) 1985-09-20 1992-04-15 Cernitin S.A. Application d'extraits de pollen de plantes à la préparation de compositions pharmaceutiques ralentissant la croissance de cellules tumorales et procédé pour leur préparation
US4731377A (en) 1986-01-31 1988-03-15 Harbor Branch Oceanographic Institute, Inc. Antitumor cyclic peroxides
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
JP2562162B2 (ja) 1986-06-09 1996-12-11 ユニバーシティ・オブ・イリノイ エクテインアシジン７２９、７４３、７４５、７５９ａ、７５９ｂおよび７７０
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4737510A (en) 1986-09-30 1988-04-12 The Board Of Trustees Of The University Of Illinois Bioactive metabolites from the caribbean sponge agelas coniferin
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4847246A (en) 1987-09-11 1989-07-11 Wilson George R Antiviral compositions derived from fireflies and their methods of use
FR2623504B1 (fr) 1987-11-25 1990-03-09 Adir Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
ATE83480T1 (de) 1988-09-05 1993-01-15 Sankyo Co Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
WO1990005731A1 (fr) 1988-11-24 1990-05-31 University Of Queensland Macromolecules cytotoxiques
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
CA2007507C (fr) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine et n-methyl-sphingosine inhibiteurs de la croissance des cellules
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
US5053559A (en) 1989-12-29 1991-10-01 Oxaco S.A. Cleavage of 1,2,4-trioxanes
KR910014122A (ko) 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
GB9212000D0 (en) 1992-06-05 1992-07-15 Univ Madrid Complutense New synthetic antitumoral compound
CA2140653A1 (fr) 1992-08-12 1994-03-03 Irene Abraham Inhibiteurs de la proteine kinase et composes connexes combines avec le taxol
US5756734A (en) 1992-09-11 1998-05-26 Pharmamar, S.A. Crambescidins: new antiviral and cytotoxic compounds from the sponge crambe crambe
ES2059259B1 (es) 1992-09-22 1995-10-01 Pharma Mar S A Pharmar Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral.
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
US6274551B1 (en) 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
GB9302044D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Cytotoxic compounds i
US5569757A (en) 1993-03-30 1996-10-29 Rinehart; Kenneth L. 9-deazaadenosine and its 5'-α-D-glycopyranoside isolated from the cyanobacterium anabaena affinis strain VS-1
GB9308111D0 (en) 1993-04-20 1993-06-02 Pharma Gen S A Active compound from a stonge
US5556777A (en) 1993-09-09 1996-09-17 Pharmamar, S.A. Immunosuppressive pharmaceutical compositions new biological activity from a marine agrobacterium sp.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5514708A (en) 1994-02-18 1996-05-07 Pharmamar, S.A. Cytotoxic metabolites from Myriapora truncata
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5681813A (en) 1994-04-06 1997-10-28 Pharma Mar, S.A. Thiodepsipeptide isolated from a marine actinomycete
ES2100124B1 (es) 1994-08-01 1998-04-01 Pharma Mar Sa Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral.
US5514705A (en) 1994-09-07 1996-05-07 Pharmamar, S.A. Epidioxymanadic acids A and B
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9422946D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Antineoplastic cyclolignan derivatives
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
GB9504662D0 (en) 1995-03-08 1995-04-26 Pharma Mar Sa Antitumour isocoumarins
US20010039041A1 (en) 1995-06-07 2001-11-08 Pharma Mar, S.A. Immunosuppressive sesbanimide compositions and methods of treatment using same
US5661175A (en) 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US5852033A (en) 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US5681847A (en) 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
EP0821068A3 (fr) 1996-03-29 1999-06-02 Rohm And Haas Company Sphinogolipides et procédé pour ceux-ci
GB9608010D0 (en) 1996-04-18 1996-06-19 Pharma Mar Sa Trunkamide A
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
EP0973518B1 (fr) 1996-10-24 2006-03-29 The Board Of Trustees Of The University Of Illinois Procedes semi-synthetiques de preparation d'analogues de didemnine
PT956033E (pt) 1996-10-24 2003-10-31 Univ Illinois SíNTESE TOTAL DE ANALOGOS AMINO HIP DE DIDEMNINA A
GB9622427D0 (en) 1996-10-28 1997-01-08 Pharma Mar Sa Antimalarial drugs
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
USRE38793E1 (en) 1997-04-15 2005-09-06 Rinehart Kenneth L Spisulosine compounds
US6107520A (en) 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
US6028077A (en) 1997-04-15 2000-02-22 Rinehart; Kenneth L. Crambescidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
AUPO656597A0 (en) 1997-05-02 1997-05-29 Australian National University, The Preparation of therapeutic compounds
ES2321462T3 (es) 1997-05-07 2009-06-05 Pharma Mar, S.A. Uso de aplidina para el tratamiento de enfermedades cardiovasculares.
GB9723206D0 (en) 1997-11-03 1998-01-07 Inst Biomar Sa New cytotoxic pyridoacridine alkaloids
US6420357B1 (en) 1997-12-23 2002-07-16 Instituto Biomar, S.A. Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge
GB9727301D0 (en) 1997-12-23 1998-02-25 Inst Biomar Sa Asmarine A and B: New cytotoxic alkaloids
GB9801741D0 (en) 1998-01-27 1998-03-25 Inst Biomar Sa New cytotoxic tris (oxazole)-containing macrolides
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
HUP0104273A3 (en) 1998-04-06 2003-12-29 Univ Illinois Semi-synthetic ecteinascidins and pharmaceutical compositions containing them
US6656948B2 (en) 1998-04-29 2003-12-02 Universidad Complutense De Madrid Cytotoxic compounds: derivatives of the pyrido[2,3,4-kl]acridine ring system
ES2248999T3 (es) 1998-05-05 2006-03-16 Pharma Mar, S.A. Cultivo de animales marinos sesiles.
ATE289810T1 (de) 1998-05-11 2005-03-15 Pharma Mar Sa Ecteinascidinderivate
GB9810998D0 (en) 1998-05-21 1998-07-22 Univ Madrid Complutense Antitumour 1,5-diazaanthraquinones
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
GB9915069D0 (en) 1999-06-28 1999-08-25 Inst Biomar Sa New indolocarbazole alkaloids from a marine actinomycete
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
ATE363910T1 (de) 1999-11-15 2007-06-15 Pharma Mar Sa Behandlung von krebserkrankungen durch aplidin
JP2003520801A (ja) 2000-01-19 2003-07-08 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク サフラマイシン−エクテイナシジン系列の化合物、それらの使用及び合成
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
BR0108448A (pt) 2000-02-16 2003-04-01 Pharma Mar Sa Derivados de tetraidrofuril óxi-e amino-substituìdos com atividade antitumor
US20030187075A1 (en) 2000-03-20 2003-10-02 Junichi Tanaka Keith Sponge antitumor compounds
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
PL358579A1 (en) 2000-04-07 2004-08-09 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
EP1280809B1 (fr) 2000-04-12 2005-07-06 Pharma Mar, S.A. Derives antitumoraux d'ecteinascidines
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
GB0010799D0 (en) 2000-05-04 2000-06-28 Inst Biomar Sa Stolonoxides
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0011927D0 (en) 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
CA2410409A1 (fr) 2000-06-06 2001-12-13 Pharma Mar, S.A. Nouveaux composes antitumoraux
GB0016020D0 (en) 2000-06-29 2000-08-23 Inst Biomar Sa New polyciclic xanthones and their use
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
ES2327210T3 (es) 2000-07-11 2009-10-27 Pharma Mar, S.A. Derivados de variolina como agentes anticancerigenos.
EP2275175B1 (fr) 2000-07-13 2016-08-24 ReCor Medical, Inc. Appareil de traitement thermique avec application d'énergie ultrasonique
GB0019117D0 (en) 2000-08-03 2000-09-27 Univ Barcelona Derivatives of variolin B
HUP0302293A3 (en) 2000-10-12 2006-04-28 Pharma Mar Sa Treatment of cancers by aplidine in conjunction with a myoprotector
KR20030038812A (ko) 2000-10-12 2003-05-16 파르마 마르, 에스.에이. 암 치료 방법
SK286421B6 (sk) 2000-10-31 2008-09-05 Pharma Mar, S. A. Prostriedok kahalalid F, súprava, rekonštituovanýa zriedený roztok s obsahom tohto prostriedku a použitie
WO2002036135A2 (fr) 2000-11-06 2002-05-10 Pharma Mar, S.A. Traitements anti-tumeur efficaces
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
JP2004521112A (ja) 2001-01-24 2004-07-15 メステックス アクチエンゲゼルシャフト 関節痛治療薬を製造することへの神経毒性物質の使用
EP1353667A1 (fr) 2001-01-25 2003-10-22 Bristol-Myers Squibb Company Formulations parenterales contenant des analogues d'epothilone
WO2002064843A1 (fr) 2001-02-09 2002-08-22 The Regents Of The University Of California Composes de la famille de l'ecteinascidine: compositions et procedes
GB0105745D0 (en) 2001-03-08 2001-04-25 Pharma Gen S A Immobilisation of ligands
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
GB0116966D0 (en) 2001-07-11 2001-09-05 Pharma Mar Sa Anittumoral compounds
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) * 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
KR20050038578A (ko) 2001-10-19 2005-04-27 파르마 마르, 에스.에이. 항종양성 화합물의 암치료에 있어서의 향상된 용도
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
EP1435990A1 (fr) 2001-10-19 2004-07-14 Pharma Mar, S.A. Composes a base de kahalalide utilisables en therapie anticancereuse
CA2462642A1 (fr) 2001-10-19 2003-04-24 Pharma Mar, S.A. Utilisation d'aplidine pour le traitement du cancer du pancreas
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0217638D0 (en) 2002-07-30 2002-09-11 Pharma Mar Sa Total synthesis of myriaporones
ES2556641T3 (es) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0218816D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa Antitumoral analogs of lamellarins
US20040033940A1 (en) 2002-08-16 2004-02-19 Pharma Mar, S.A. Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP
BR0315489A (pt) 2002-10-18 2005-08-23 Pharma Mar Sau Composição antitumorais
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
GB0303940D0 (en) 2003-02-20 2003-03-26 Pharma Mar Sau Solid phase synthesis of antitumoral compounds
DE602004027888D1 (de) 2003-02-20 2010-08-12 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihr
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
NZ541634A (en) 2003-03-12 2008-08-29 Pharma Mar Sa Improved antitumoral treatments
KR101160320B1 (ko) 2003-03-12 2012-06-26 파르마 마르 에스.에이. 다발 골수종 치료를 위한 아플리딘
CN1819837A (zh) 2003-03-21 2006-08-16 玛德琳·M.·茹利 Tamandarin类似物及其片段以及制备和使用方法
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
WO2005005601A2 (fr) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions et methodes de traitement et de diagnostic du cancer
GB0314726D0 (en) 2003-06-24 2003-07-30 Inst Biomar Sa New cytotoxic depsipeptides
US7378410B2 (en) 2003-07-25 2008-05-27 Novartis Ag Substituted lactams and their use as anti-cancer agents
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
EP1680415B1 (fr) 2003-10-09 2008-12-31 Abbott Laboratories Derives de pyrrolidinyle- uree utilises comme inhibiteurs de l'angiogenese
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PT1689404E (pt) 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
US20080255132A1 (en) 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
DE102004011809A1 (de) 2004-03-11 2005-09-29 Robert Bosch Gmbh Magnetsensoranordnung
GB0408958D0 (en) 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
WO2005118584A2 (fr) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Nouveaux analogues de saframycine utilises en tant qu'agents therapeutiques
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
WO2006005602A2 (fr) 2004-07-09 2006-01-19 Pharma Mar, S.A. Marqueurs moleculaires de pronostic
JP2008514688A (ja) 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
UA87877C2 (en) 2004-10-26 2009-08-25 Фарма Мар С.А., Сосьедад Униперсональ Pegylated liposomal doxorubicin in combination with ecteinescidin 743
PT1658848E (pt) 2004-10-29 2007-11-05 Pharma Mar Sa Formulações contendo ecteinascidina e um dissacarídeo
EP1817059A2 (fr) 2004-12-01 2007-08-15 Genentech, Inc. Conjugues medicament anticorps et procedes correspondants
WO2006066183A2 (fr) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Nouveaux analogues de saframycine utilises en tant qu'agents therapeutiques
MX2007013683A (es) 2005-05-03 2007-12-03 Pharma Mar Sa Tetrahidropirimidinas antitumorales.
GB0515673D0 (en) 2005-08-01 2005-09-07 Pharma Mar Sa Antitumoral compounds
RU2008107974A (ru) 2005-08-02 2009-09-10 Фарма Мар, С.А. (Es) Гены, участвующие в биосинтезе тиокоралина и его гетерологичном продуцировании
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0523098D0 (en) 2005-11-14 2005-12-21 Pharma Mar Sa Antitumoral compounds
WO2007062413A2 (fr) 2005-11-25 2007-05-31 University Of Medicine And Dentistry Of New Jersey Utilisation d'inhibiteurs du parp-1
ES2276629B1 (es) 2005-12-15 2009-04-01 Pharma Mar, S.A. Compuestos antitumorales.
ES2288107B1 (es) 2006-01-27 2008-11-01 Fundacion Imabis Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanita Derivados aciclicos saturados e insaturados de cadena larga de sulfamidas como activadores especificos de receptores ppar-alfa.
DK2029155T3 (en) 2006-02-28 2016-08-01 Pharma Mar Sa IMPROVED treatment of multiple myeloma
CA2652035A1 (fr) 2006-05-12 2007-11-22 Pharma Mar, S.A. Traitements anticancereux
EP1864682A1 (fr) 2006-06-09 2007-12-12 Sanofi-Aventis Dérivés de la Leptomycine
UA97369C2 (ru) 2006-06-16 2012-02-10 Фарма Мар, С.А. Противоопухолевые соединения дигидропиран-2-она и фармацевтическая композиция на их основе
AU2008313627A1 (en) 2007-10-19 2009-04-23 Pharma Mar, S.A. Improved antitumoral treatments
RU2010119922A (ru) 2007-10-19 2011-11-27 Фарма Мар, С.А. (Es) Усовершенствованное противоопухолевое лечение
US20100267732A1 (en) 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
US8748388B2 (en) 2007-12-14 2014-06-10 Pharma Mar, S.A. Antitumoral compounds
UA106967C2 (uk) 2007-12-20 2014-11-10 Фарма Мар, С.А. Протипухлинні аналоги пептидів, фармацевтична композиція, спосіб одержання сполук та проміжні сполуки
WO2009095480A1 (fr) 2008-01-30 2009-08-06 Pharma Mar, S.A. Traitements antitumoraux améliorés
EP2262522A1 (fr) 2008-03-07 2010-12-22 Pharma Mar, S.A. Traitements anti-tumoraux améliorés
AU2009221720A1 (en) 2008-03-07 2009-09-11 Pharma Mar, S.A. Improved anticancer treatments
AU2009246130A1 (en) 2008-05-16 2009-11-19 Pharma Mar, S.A. Combination therapy with PM00 104 and another antitumor agent
WO2009138509A1 (fr) 2008-05-16 2009-11-19 Pharma Mar, S.A. Traitements du myélome multiple
TR201906123T4 (tr) 2008-05-23 2019-05-21 Wyeth Llc P13 kinazı ve mtor inhibitörleri olarak triazin bileşikleri.
US20110118343A1 (en) 2008-07-03 2011-05-19 Pharma Mar, S. A. Antitumoral Macrolides
EP2303332B1 (fr) 2008-07-15 2014-12-31 Genentech, Inc. Conjugués de dérivés d anthracycline, procédé de préparation associé et utilisation comme composés antitumoraux
CA2730663A1 (fr) 2008-07-17 2010-01-21 Pharma Mar, S.A. Composes anticancereux
NZ593169A (en) 2008-12-19 2013-07-26 Pharma Mar Sa Anticancer compounds
WO2010149688A2 (fr) 2009-06-24 2010-12-29 Pharma Mar, S.A. Composés anticancéreux
UA112746C2 (uk) 2010-04-27 2016-10-25 Фарма Мар, С.А. Протиракові стероїдні лактони, ненасичені в положенні 7(8)
JP6037337B2 (ja) * 2010-05-25 2016-12-07 ファルマ、マール、ソシエダード、アノニマＰｈａｒｍａ Ｍｒｓ，Ｓ．Ａ． エクチナサイジン化合物の製造のための合成方法
RU2605335C2 (ru) 2010-11-12 2016-12-20 Фарма Мар, С.А. Комбинированная терапия противоопухолевым алкалоидом
DE102012211024A1 (de) 2012-06-27 2014-01-02 Robert Bosch Gmbh Verfahren zum Betreiben eines Fahrzeuges
JP5922518B2 (ja) 2012-07-20 2016-05-24 浜松ホトニクス株式会社 シンチレータパネル及び放射線検出器
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
MA45656A (fr) 2016-07-14 2021-03-24 Pfizer Nouveaux pyrimidine carboxamides utilisées comme inhibiteurs de l'enzyme vanin-1
JOP20190254A1 (ar) * 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
CY1121885T1 (el) 2020-10-14
RS64174B1 (sr) 2023-05-31
LT4047002T (lt) 2023-05-10
HUE046109T2 (hu) 2020-02-28
EP3615544A1 (fr) 2020-03-04
SI4101855T1 (sl) 2024-03-29
KR102491180B1 (ko) 2023-01-20
EP4047002A1 (fr) 2022-08-24
TN2019000211A1 (en) 2021-01-07
LT3395821T (lt) 2019-08-12
AU2018260314C1 (en) 2022-04-21
JOP20190254A1 (ar) 2019-10-27
AU2022200249B1 (en) 2022-02-10
JP6501946B2 (ja) 2019-04-17
JP2018188432A (ja) 2018-11-29
KR102510975B1 (ko) 2023-03-16
FI4101855T3 (fi) 2023-09-22
US20210246146A1 (en) 2021-08-12
PT3395820T (pt) 2019-08-07
ECSP19083967A (es) 2019-12-27
CN114736219B (zh) 2024-06-07
RS59173B1 (sr) 2019-10-31
ME03466B (fr) 2020-01-20
MX2021016058A (es) 2022-02-03
DK3615544T3 (da) 2023-05-30
ES2741901T3 (es) 2020-02-12
ME03467B (fr) 2020-01-20
DK3395820T3 (da) 2019-08-12
JP6501947B2 (ja) 2019-04-17
AU2018260314A1 (en) 2019-10-31
MD3395820T2 (ro) 2019-10-31
EP3395820A1 (fr) 2018-10-31
SI3395821T1 (sl) 2019-09-30
PL3395821T3 (pl) 2019-10-31
HRP20191443T1 (hr) 2019-11-15
EP3395821B1 (fr) 2019-05-15
HK1255938B (zh) 2020-04-29
WO2018197663A1 (fr) 2018-11-01
IL295044B1 (en) 2023-07-01
MA44020B1 (fr) 2019-08-30
MD3395821T2 (ro) 2019-10-31
HK1255941B (zh) 2020-04-29
JP7186723B2 (ja) 2022-12-09
CN114736219A (zh) 2022-07-12
RS64200B1 (sr) 2023-06-30
BR112019022282A2 (pt) 2020-05-19
EP3395821A1 (fr) 2018-10-31
DK3395821T3 (da) 2019-08-19
HUE062032T2 (hu) 2023-09-28
EP4101855B9 (fr) 2024-01-03
MD3615544T2 (ro) 2023-08-31
IL270153A (fr) 2019-12-31
KR20210126791A (ko) 2021-10-20
ES2740073T3 (es) 2020-02-05
US20180312529A1 (en) 2018-11-01
MX2019012812A (es) 2020-01-14
IL270153B1 (en) 2023-06-01
US11332480B2 (en) 2022-05-17
HUE062157T2 (hu) 2023-10-28
IL270153B2 (en) 2023-10-01
LT4101855T (lt) 2023-08-25
IL295044B2 (en) 2023-11-01
IL289963A (en) 2022-03-01
EP4101855A1 (fr) 2022-12-14
PL3395820T3 (pl) 2019-11-29
PL4101855T3 (pl) 2023-12-27
EP4047002B1 (fr) 2023-03-08
HUE045641T2 (hu) 2020-01-28
LT3615544T (lt) 2023-05-10
JP7490835B2 (ja) 2024-05-27
AU2018260314B2 (en) 2021-12-09
DK4047002T3 (da) 2023-05-01
AU2022200250B1 (en) 2022-02-10
HRP20230433T1 (hr) 2023-07-07
ES2944344T3 (es) 2023-06-20
RS64686B1 (sr) 2023-11-30
ES2960063T3 (es) 2024-02-29
RS59174B1 (sr) 2019-10-31
AU2022201657A1 (en) 2022-03-31
EP4101855B1 (fr) 2023-08-02
TW202202509A (zh) 2022-01-16
FI4047002T3 (fi) 2023-05-22
AU2022200250C1 (en) 2022-06-23
SG10201913300YA (en) 2020-03-30
JP2020517709A (ja) 2020-06-18
MA44021B1 (fr) 2019-08-30
MA44020A (fr) 2018-10-31
PT3395821T (pt) 2019-08-27
CN114751920B (zh) 2024-06-07
JP2023052597A (ja) 2023-04-11
MA44021A (fr) 2019-05-15
HRP20231233T1 (hr) 2024-01-19
MD4101855T2 (ro) 2023-12-31
US11339180B2 (en) 2022-05-24
CY1126061T1 (el) 2023-11-15
MD4047002T2 (ro) 2023-08-31
JP7422812B2 (ja) 2024-01-26
HRP20230455T1 (hr) 2023-07-21
US20220242883A1 (en) 2022-08-04
LT3395820T (lt) 2019-08-12
CN117865987A (zh) 2024-04-12
PL4047002T3 (pl) 2023-07-24
DK4101855T3 (da) 2023-11-06
MX2021016054A (es) 2022-06-01
EP3615544B9 (fr) 2024-01-03
HUE063736T2 (hu) 2024-01-28
CA3061518A1 (fr) 2018-11-01
TW202344509A (zh) 2023-11-16
SG11201909841RA (en) 2019-11-28
PL3615544T3 (pl) 2023-07-17
KR20220109495A (ko) 2022-08-04
TWI807411B (zh) 2023-07-01
JP2022130682A (ja) 2022-09-06
ES2944579T3 (es) 2023-06-22
CL2019003057A1 (es) 2020-02-21
CN110621678A (zh) 2019-12-27
SI3395820T1 (sl) 2019-09-30
EP3615544B1 (fr) 2023-03-22
HRP20191442T1 (hr) 2019-11-15
KR20200012846A (ko) 2020-02-05
PH12019550224A1 (en) 2020-10-12
MY198004A (en) 2023-07-25
FI3615544T3 (fi) 2023-05-23
KR102492283B1 (ko) 2023-01-27
UY37706A (es) 2018-11-30
IL295044A (en) 2022-09-01
US20210070775A1 (en) 2021-03-11
AU2022200249C1 (en) 2022-06-23
CN114751920A (zh) 2022-07-15
EP3395820B1 (fr) 2019-05-15
SI3615544T1 (sl) 2023-07-31
TN2019000210A1 (en) 2021-01-07
IL289963B1 (en) 2023-06-01
US11713325B2 (en) 2023-08-01
TWI742273B (zh) 2021-10-11
SI4047002T1 (sl) 2023-07-31
US20240166666A1 (en) 2024-05-23
TW201906850A (zh) 2019-02-16
US10538535B2 (en) 2020-01-21
CY1121884T1 (el) 2020-10-14
IL289963B2 (en) 2023-10-01
JP2018188431A (ja) 2018-11-29
ZA201907119B (en) 2021-07-28

Similar Documents

Publication Publication Date Title
CO2019011967A2 (es) Compuestos antitumorales
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CL2018001230A1 (es) Tratamiento de osteoartritis
CL2018001591A1 (es) Compuestos útiles como inhibidores de cinasa.-
MX2018006148A (es) Inhibidores de cxcr2.
GEP20186933B (en) Substituted dihydroisoquinoline compounds
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
PH12019500664A1 (en) New isoxazolyl ether derivatives as gaba a alpha5 pam
EA201792287A1 (ru) Способы лечения рака
MX2018001576A (es) Piridinas y su uso en el tratamiento del cancer.
MX2019009356A (es) Sulfinilpiridinas y su uso en el tratamiento del cancer.
BR112019003130A2 (pt) agonista de ppargama para tratamento de cânceres de sangue
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
WO2018146390A8 (fr) Utilisation d'un compose appartenant a la famille des diuretiques pour traiter le cancer
MX2018001575A (es) Compuestos triciclicos y su uso en el tratamiento del cancer.
EA201992557A1 (ru) Противоопухолевые соединения
UA108340U (uk) Морфолінію 1-н-бутилтеобромін-8-ілтіоацетат, який виявляє діуретичну дію
TH174565B (th) อนุพันธ์เตตระไฮโดรไพรานิล เบนซาไมด์
UA90821U (uk) Сполука 1-1-діетилкарбоксі-2-ізопропокси-2-трифторметилетилен з потенційними фізіологічними властивостями
UA90817U (uk) Сполука 1,1-діетилкарбокси-2-трифторметил-2-(5'-бромуридил-1'-)етилен з потенційними фізіологічними властивостями